1. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience
- Author
-
Eugenia Resmini, Emanuela Zarra, Silvia Dotti, Giulia Rotondi, Angelo Vincenzo Cornaghi, Sara Madaschi, Elena Cimino, Giulia Massari, Letizia Chiara Pezzaioli, Caterina Buoso, Marco Sandri, and Angela Girelli
- Subjects
Advanced Hybrid Closed-Loop systems ,GRI ,CGM metrics ,Type 1 diabetes mellitus ,Medicine - Abstract
Abstract Background Advanced Hybrid Closed-Loop system (AHCL) has profoundly changed type 1 diabetes therapy. This study primarily aimed to assess the impact on Glycemia Risk Index (GRI) and other continuous glucose monitoring (CGM) metrics when switching from one of four insulin strategies to AHCL in type 1 adult patients. Methods A single-center, retrospective pre/post observational study; 198 patients (age 44.4 ± 12.7 years, 115 females/83 males, diabetes duration 24.7 ± 11.6 years, HbA1c 7.4 ± 1%), treated with different insulin therapies (MDI, CSII, SAP with PLGS, HCL) were assessed before and after switching to an AHCL (MiniMed 780G, Diabeloop Roche, Tandem Control-IQ) at 1, 3, 6, and 12 months. Mixed-effects multivariable regression models were used to estimate the mean pre/post variations at different time points, adjusted for potential confounders. Results A month after the switch, there was an improvement in CGM metrics and HbA1c for all patients: GRI −10.7, GMI −0.27%, CV −2.1%, TAR>250 −3.7%, TAR180-250 −5.6%, TIR + 9.7%, HbA1c −0.54% (all p 250 at T1 (for all p
- Published
- 2024
- Full Text
- View/download PDF